Relmada Therapeutics, Inc.Relmada Therapeutics, Inc.Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪116.77 M‬USD
−3.28USD
‪−98.79 M‬USD
‪25.39 M‬
Beta (1Y)
1.65

About Relmada Therapeutics, Inc.

CEO
Sergio Traversa
Headquarters
Coral Gables
Employees (FY)
20
Founded
2012
FIGI
BBG003MKSL16
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of RLMD is 3.93 USD — it has increased by 1.42% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Relmada Therapeutics, Inc. stocks are traded under the ticker RLMD.
Relmada Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
RLMD stock is 6.77% volatile and has beta coefficient of 1.65. Check out the list of the most volatile stocks — is Relmada Therapeutics, Inc. there?
RLMD earnings for the last quarter are −0.73 USD per share, whereas the estimation was −0.91 USD resulting in a 20.13% surprise. The estimated earnings for the next quarter are −0.83 USD per share. See more details about Relmada Therapeutics, Inc. earnings.
Yes, you can track Relmada Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
RLMD stock has fallen by 12.19% compared to the previous week, the month change is a 14.86% fall, over the last year Relmada Therapeutics, Inc. has showed a 49.81% increase.
RLMD net income for the last quarter is ‪−25.17 M‬ USD, while the quarter before that showed ‪−22.00 M‬ USD of net income which accounts for −14.38% change. Track more Relmada Therapeutics, Inc. financial stats to get the full picture.
Today Relmada Therapeutics, Inc. has the market capitalization of ‪116.77 M‬, it has decreased by 3.84% over the last week.
No, RLMD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RLMD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Relmada Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
RLMD reached its all-time high on Jun 25, 2020 with the price of 54.00 USD, and its all-time low was 1.81 USD and was reached on Dec 8, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 23, 2024, the company has 20.00 employees. See our rating of the largest employees — is Relmada Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Relmada Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Relmada Therapeutics, Inc. stock shows the sell signal. See more of Relmada Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Relmada Therapeutics, Inc. future price: according to them, RLMD price has a max estimate of 25.00 USD and a min estimate of 3.00 USD. Read a more detailed Relmada Therapeutics, Inc. forecast: see what analysts think of Relmada Therapeutics, Inc. and suggest that you do with its stocks.